{"id":"adv-tk","safety":{"commonSideEffects":[{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Injection site reactions"}]},"_chembl":{"chemblId":"CHEMBL606519","moleculeType":"Small molecule","molecularWeight":"223.16"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"AdV-tk is a replication-competent adenovirus engineered to express the herpes simplex virus thymidine kinase (HSV-tk) gene. The virus selectively replicates within tumor cells, causing direct cytolysis. The expressed HSV-tk enzyme phosphorylates the prodrug ganciclovir into a toxic nucleotide analog that further kills tumor cells and bystander cells. This combination approach leverages oncolytic viral activity, prodrug activation, and immunogenic cell death to trigger anti-tumor immunity.","oneSentence":"AdV-tk is an oncolytic adenovirus expressing herpes simplex virus thymidine kinase that replicates in tumor cells and sensitizes them to ganciclovir, triggering both direct viral lysis and immune activation.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:59:42.816Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic pancreatic cancer"},{"name":"Ovarian cancer"}]},"trialDetails":[{"nctId":"NCT07332000","phase":"PHASE2","title":"A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec","status":"RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2025-10-30","conditions":"Prostate Cancer Patients Treated by Radiotherapy, Prostate Cancer (Adenocarcinoma)","enrollment":45},{"nctId":"NCT06914479","phase":"PHASE1","title":"Virus-Based Gene Therapy (AdV-HSV1-TK and AdV-Flt3L) in Combination With Valacyclovir for the Treatment of Pediatric and Young Adult Patients With Resectable, Recurrent Primary Malignant Brain Tumors","status":"RECRUITING","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2026-06-01","conditions":"Recurrent Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Malignant Brain Neoplasm, Resectable Brain Neoplasm","enrollment":11},{"nctId":"NCT06102525","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma","status":"RECRUITING","sponsor":"Rznomics, Inc.","startDate":"2024-10-08","conditions":"Glioblastoma","enrollment":43},{"nctId":"NCT04495153","phase":"PHASE2","title":"CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2020-10-13","conditions":"Non Small Cell Lung Cancer","enrollment":90},{"nctId":"NCT02768363","phase":"PHASE2","title":"Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2016-05","conditions":"Prostate Cancer","enrollment":187},{"nctId":"NCT01436968","phase":"PHASE3","title":"Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2011-09","conditions":"Prostate Cancer","enrollment":711},{"nctId":"NCT03131037","phase":"PHASE1","title":"Intratumoral Gene Mediated Cytotoxic Immunotherapy in Patients With Resectable Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Candel Therapeutics, Inc.","startDate":"2017-05-04","conditions":"Lung Cancer","enrollment":12},{"nctId":"NCT03576612","phase":"PHASE1","title":"GMCI, Nivolumab, and Radiation Therapy in Treating Patients With Newly Diagnosed High-Grade Gliomas","status":"COMPLETED","sponsor":"Candel Therapeutics, Inc.","startDate":"2018-02-27","conditions":"Glioma, Malignant","enrollment":41},{"nctId":"NCT06676891","phase":"","title":"Expanded Access Program for GBM Subjects","status":"AVAILABLE","sponsor":"Rznomics, Inc.","startDate":"","conditions":"Glioblastoma","enrollment":""},{"nctId":"NCT03603405","phase":"PHASE1, PHASE2","title":"HSV-tk and XRT and Chemotherapy for Newly Diagnosed GBM","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2018-02-28","conditions":"Glioblastoma, Anaplastic Astrocytoma","enrollment":62},{"nctId":"NCT03596086","phase":"PHASE1, PHASE2","title":"HSV-tk + Valacyclovir + SBRT + Chemotherapy for Recurrent GBM","status":"RECRUITING","sponsor":"David Baskin MD","startDate":"2017-12-11","conditions":"Glioblastoma Multiforme, Astrocytoma, Grade III","enrollment":62},{"nctId":"NCT03004183","phase":"PHASE2","title":"SBRT and Oncolytic Virus Therapy Before Pembrolizumab for Metastatic TNBC and NSCLC","status":"COMPLETED","sponsor":"The Methodist Hospital Research Institute","startDate":"2017-07-01","conditions":"Metastatic Non-small Cell Lung Cancer, Metastatic Triple-negative Breast Cancer","enrollment":57},{"nctId":"NCT01811992","phase":"PHASE1","title":"Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2014-04","conditions":"Malignant Glioma, Glioblastoma Multiforme","enrollment":19},{"nctId":"NCT00589875","phase":"PHASE2","title":"Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma","status":"COMPLETED","sponsor":"Candel Therapeutics, Inc.","startDate":"2007-03","conditions":"Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma","enrollment":52},{"nctId":"NCT02446093","phase":"PHASE2","title":"Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Candel Therapeutics, Inc.","startDate":"2015-10","conditions":"Borderline Resectable Pancreatic Adenocarcinoma","enrollment":54},{"nctId":"NCT02831933","phase":"PHASE2","title":"Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma","status":"TERMINATED","sponsor":"Eric Bernicker, MD","startDate":"2017-02-15","conditions":"Lung Squamous Cell Carcinoma Stage IV, Nonsquamous Nonsmall Cell Neoplasm of Lung, Metastatic Uveal Melanoma","enrollment":11},{"nctId":"NCT01997190","phase":"PHASE1","title":"Intrapleural AdV-tk Therapy in Patients With Malignant Pleural Effusion","status":"COMPLETED","sponsor":"Candel Therapeutics, Inc.","startDate":"2013-10","conditions":"Malignant Pleural Effusion, Lung Cancer, Mesothelioma","enrollment":19},{"nctId":"NCT00634231","phase":"PHASE1","title":"A Phase I Study of AdV-tk + Prodrug Therapy in Combination With Radiation Therapy for Pediatric Brain Tumors","status":"COMPLETED","sponsor":"Candel Therapeutics, Inc.","startDate":"2010-10","conditions":"Malignant Glioma, Recurrent Ependymoma","enrollment":8},{"nctId":"NCT00638612","phase":"PHASE1","title":"AdV-tk Therapy With Surgery and Chemoradiation for Pancreas Cancer (PaTK01)","status":"COMPLETED","sponsor":"Candel Therapeutics, Inc.","startDate":"2008-08","conditions":"Pancreatic Adenocarcinoma, Pancreatic Cancer","enrollment":27},{"nctId":"NCT00751270","phase":"PHASE1","title":"Phase 1b Study of AdV-tk + Valacyclovir Combined With Radiation Therapy for Malignant Gliomas","status":"COMPLETED","sponsor":"Candel Therapeutics, Inc.","startDate":"2005-11","conditions":"Malignant Glioma, Glioblastoma Multiforme, Anaplastic Astrocytoma","enrollment":15},{"nctId":"NCT03281382","phase":"PHASE1","title":"Phase 1 Trial of Interleukin 12 Gene Therapy for Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Henry Ford Health System","startDate":"2017-07-01","conditions":"Metastatic Pancreatic Cancer","enrollment":12},{"nctId":"NCT03541928","phase":"PHASE2","title":"Phase II High Risk Prostate Cancer Trial Using Gene & Androgen Deprivation Therapies, Radiotherapy, & Surgery","status":"UNKNOWN","sponsor":"The Methodist Hospital Research Institute","startDate":"2018-08-02","conditions":"High-risk Prostate Cancer, Prostate Cancer","enrollment":60},{"nctId":"NCT03029871","phase":"PHASE1","title":"Oncolytic Adenovirus-Mediated Gene Therapy for Lung Cancer","status":"WITHDRAWN","sponsor":"Benjamin Movsas, M.D.","startDate":"2017-01-13","conditions":"Non-small Cell Lung Cancer Stage I","enrollment":""},{"nctId":"NCT00002824","phase":"PHASE1","title":"Gene Therapy in Treating Patients With Primary Brain Tumors","status":"COMPLETED","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"1996-02","conditions":"Brain and Central Nervous System Tumors","enrollment":""},{"nctId":"NCT03313596","phase":"PHASE3","title":"Multicenter RCT of ADV-TK Gene Therapy Improving the Outcome of Liver Transplantation for Advanced HCC","status":"UNKNOWN","sponsor":"Huazhong University of Science and Technology","startDate":"2013-03","conditions":"Hepatocellular Carcinoma","enrollment":180},{"nctId":"NCT01913106","phase":"PHASE1, PHASE2","title":"HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer","status":"RECRUITING","sponsor":"The Methodist Hospital Research Institute","startDate":"2007-06","conditions":"Prostatic Neoplasms","enrollment":25},{"nctId":"NCT00005057","phase":"PHASE1","title":"Gene Therapy and Ganciclovir in Treating Patients With Stage IV Melanoma","status":"COMPLETED","sponsor":"National Human Genome Research Institute (NHGRI)","startDate":"2000-03","conditions":"Melanoma (Skin)","enrollment":""},{"nctId":"NCT02202564","phase":"PHASE2","title":"Preliminary Results for the Double-dose Adenovirus-mediated Adjuvant Therapy Improving Outcome of Liver Transplantation in Patients With Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Huazhong University of Science and Technology","startDate":"2006-10","conditions":"Liver Cancer, Hepatocellular Carcinoma","enrollment":81},{"nctId":"NCT00870181","phase":"PHASE2","title":"ADV-TK Improves Outcome of Recurrent High-Grade Glioma","status":"COMPLETED","sponsor":"Huazhong University of Science and Technology","startDate":"2008-01","conditions":"Malignant Glioma of Brain, Glioblastoma","enrollment":47},{"nctId":"NCT00844623","phase":"PHASE1","title":"TK-based Suicide Gene Therapy for Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Clinica Universidad de Navarra, Universidad de Navarra","startDate":"2002-12","conditions":"Carcinoma, Hepatocellular","enrollment":10},{"nctId":"NCT00300521","phase":"PHASE2","title":"Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Beijing Chao Yang Hospital","startDate":"2000-09","conditions":"Hepatocellular Carcinoma, Liver Transplantation","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":52,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["adenovirus-thymidine kinase","Aglatimagene Besadenovec"],"phase":"phase_3","status":"active","brandName":"AdV-tk","genericName":"AdV-tk","companyName":"Candel Therapeutics, Inc.","companyId":"candel-therapeutics-inc","modality":"Biologic","firstApprovalDate":"","aiSummary":"AdV-tk is an oncolytic adenovirus expressing herpes simplex virus thymidine kinase that replicates in tumor cells and sensitizes them to ganciclovir, triggering both direct viral lysis and immune activation. Used for Metastatic pancreatic cancer, Ovarian cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}